

Funding support

Projects	Available	End
1. Research platforms		
1.1 Multicentre Observational Study of MDS Patients in Switzerland – Swiss MDS Registry		
- Insel	5 K	Non limited
- Pharma (Novartis/Celgene/Roche)	40 K	Non limited
- Stiftung für Krebsbekämpfung	20 K	2020 ff
	65 K	
1.2 Swiss Cohort for the Characterization of Pathogenesis and Clonal Evolution in Myeloid Neoplasms - Swiss MDS Biobank (multicentric biobanking)		
1.3 Single-centre, observational, prospective study aiming for longitudinal sampling and collection of corresponding health-related data in patients with malignant and non-malignant haematological disorders. Cohort for Haematological Disorders (HÄM-COHORT) (monocentric biobanking)		
- Biobank Services, ZLM, Inselspital Bern	135 K	5/2022
- PHRT Pioneer Project Proposal	50K	1/2022
	185K	

2. National working packages (WP) on the Swiss MDS Registry platform		
2.1 WP1: Impact of Guidelines Adherence on Effectiveness and Safety of Health Care Provided to MDS Patients		
- Health Services Research Grant from Swiss Cancer Research (HSR-4085-11_2016)	135K	7/2021
- I-CARE for MDS (SAKK 33/18: budget covered to 70% by SAKK, 30% need to be covered by other institutions)	900K	12/2024
2.2 WP2: The Role of Innate Immunity in Chronic Myelomonocytic Leukaemia and Myelodysplastic Syndromes (MDS 18-01)		
- Collaboration with Prof. Ramanjaneyulu Allam		
- Krebsliga or SNSF	planned	
2.3 WP3: Exploration of the Influence of Free Plasma Iron Toxicity and Redox-Stress on Immune Subversion and Clonal Progression in Patients with Myelodysplastic Syndromes		
- Collaboration with Prof. Ulrike Bacher, PD Dr. Michaela Fux		
- Dissertation Alessandro Vella		
- Novartis	10K	2020
- Subsequent grants SNSF, Krebsliga, Pharma	planned	
2.4 WP4: Investigation of the role of cytomorphology and histopathology for the diagnosis of MDS in the era of modern genetics - Collaboration with Prof. Ulrike Bacher		
- None	published	
2.5 WP5: The Role of Extracellular Vesicles in Myelodysplastic Syndromes (BASEC: 2016_01052) (Manfred Heller) (MDS16-01)		
- Industry, Krebsliga or SNSF	planned	
2.6. WP6: Characterization of Oncospecific Protein Isoforms as Targets for Myelodysplastic Syndromes		
- Cooperation with USZ (Stephan Balabanov, Markus G. Manz), Nexus ETH (Daniel Stekhoven), Clinical Proteotype Analysis Centre ETH (Bernd Wollscheid) und Genome Center in Geneva (Dr. Keith Harshman. Prof. Prof. Ioannis Xenarios).		
- Pioneer Project Proposals	447K	1/2022
2.7. Other clinical studies using registry data		
- for master- and doctor-thesis		
	1500K	

3. International projects on the Swiss MDS Registry platform		
3.1 IP1: CMML First Line Treatment		
- Cooperation: Lisa Pleyer (Austria)		
3.2 IP2: Genetic background of MDS-MPN-U		
- Cooperation: Francesc Sole (Spain)		
3.3 IP3: Genetic background of hypoplastic MDS		
- Cooperation: Felicitas Thol (Germany)		

4. Translational research		
Convergence of Genetic and Epigenetic Alterations in Targetable Oncogenic Pathways in High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia		
- Inselspital Research Grant number 84800751	80K	5/2017
- Bernese Cancer League	80K	12/2018
	160K	
Identification and Validation of Bypassing Oncogenic Pathways in Patients with Relapsed/Refractory Myeloid Neoplasms		
- SNSF	Funding request	